A Strategic Opportunity for UK–India MedTech Collaboration
Microbira was honoured to join the UK–India MedTech, Diagnostics and Digital Health Cohort, organised by the Foreign, Commonwealth and Development Office. This four-day programme in New Delhi and Mumbai brought together innovative UK companies and India’s most influential healthcare organisations, creating an exceptional opportunity to deepen UK–India MedTech collaboration.
The delegation included several leading UK companies, and the programme began with a high-level meeting at India’s national regulator, CDSCO. This session offered essential insights into India’s regulatory environment. In addition, it highlighted future pathways for regulatory alignment and innovation.
Engagements with Industry Leaders
The first full day continued with a major roundtable hosted by FICCI. Microbira and other delegates met 25+ C-suite stakeholders representing diagnostic laboratories, hospital groups, manufacturers, distributors, investors and advisors. The discussion was supported by Anna Shotbolt, His Majesty’s Deputy Trade Commissioner for South Asia, who emphasised the growing strength of UK–India MedTech collaboration.
Later, everyone was welcomed by Dr Lal Path Labs, India’s second-largest diagnostic chain, for focused discussions on innovation, workflow translation, and partnership opportunities.
Expanding Networks Across India
The cohort then travelled to Mumbai for a programme arranged with the SME Chamber of Commerce, involving senior representatives from Western India’s MedTech, diagnostics and hospital networks. Meetings with Metropolis Healthcare and Agilus Diagnostics — India’s leading and fastest-growing diagnostic chains — provided invaluable insight into operational scale, patient pathways and data-driven diagnostics across India.
These engagements demonstrated the enormous potential for UK–India MedTech collaboration, especially in areas such as microbiology, diagnostics, AI-enabled workflows and scalable healthcare delivery.
Future Outlook
Microbira extends sincere thanks to the outstanding Healthcare, Life Sciences and Chemicals team at the British High Commission in India — Edna Dsouza, Ashwin Ravindran, Aman Chawla, Risha Rajput and Sangeeta Marmate — for their exceptional coordination and support throughout the cohort.
This visit marked a significant milestone in Microbira’s international strategy, reinforcing the value of strong bilateral partnerships and the exciting future of UK–India MedTech collaboration.
To stay up to date with our work across the UK and India, follow us on LinkedIn: Microbira and Mcirobira India.
